Improvements in lung function, SGRQ total score and ACQ-5 score were also seen with mepolizumab versus placebo across most age and lung function subgroups. Across age at asthma onset, lung function and airway reversibility subgroups, mepolizumab reduced the rate of clinically significant exacerbations by 49РІР‚вЂњ63% versus placebo. Overall, 936 patients received mepolizumab 100Р’В mg SC or placebo. Analyses were performed by baseline age of asthma onset (РІР‚вЂ°80) airway reversibility (reversible non-reversible ) perennial and/or seasonal allergen sensitivity (yes/no) asthma control (uncontrolled partial/complete control ). The primary endpoint was the annual rate of clinically significant exacerbations other outcomes included the proportion of patients with no exacerbations and changes from baseline in pre-bronchodilator forced expiratory volume in 1Р’В s (FEV 1), St GeorgeРІР‚в„ўs Respiratory Questionnaire (SGRQ) total score and Asthma Control Questionnaire (ACQ)-5 score. Patients agedРІР‚вЂ°РІвЂ°ТђРІР‚вЂ°12Р’В years with severe eosinophilic asthma and a history of exacerbations were randomised to receive placebo (MENSA/MUSCA), mepolizumab 75Р’В mg intravenously (MENSA) or 100Р’В mg subcutaneously (SC) (MENSA/MUSCA) every 4Р’В weeks for 32 (MENSA) or 24 (MUSCA) weeks. This was a post hoc meta-analysis of data from the Phase III MENSA (NCT01691521/MEA115588) and MUSCA (NCT02281318/200862) studies. This analysis assessed whether select baseline patient characteristics could prognosticate mepolizumab efficacy in severe eosinophilic asthma.

Severe asthma is associated with a broad range of phenotypes and clinical characteristics.

Hoc rhinoceros 6